|
Global GenomicsSM AB (Stockholm, Sweden) announced today
the availability of an improved version of its tangerine® whole-genome
expression profiling technology, substantially increasing coverage
of the human, mouse and rat transcriptomes.
By assembling transcriptomes much like genomes are assembled
from individual sequence reads, researchers at Global Genomics
were able to discover novel splice variants and alternative
polyadenylation sites, as well as to correct sequencing errors
in publically available mRNA sequences.
– Although the number of genes has been revised downwards several
times, most recently to about 22 000, much of the complexity
of mammalian genomes is produced by alternative splicing and
alternative polyadenylation, said CTO Sten Linnarsson. Our latest assembly
of the human transcriptome contains well over 168 000 different
transcripts, all derived from experimental data.
– The new transcriptome assemblies represent a significant step forward
for tangerine gene expression profiling. We believe that microarray
manufacturers seeking to improve the scope and accuracy of their
probe sets would benefit from these same features – sequence
error correction, splice variant assembly and the mapping of
alternative polyadenylation, said CEO Ulf Boberg.
The mouse transcriptome (103 000 transcripts) is available immediately
for expression profiling using Global Genomics’ tangerine technology.
The human (168 000) and rat (43 000) transcriptomes will be
commercially available soon.
About Global Genomics
Global Genomics develops and out-licenses innovative tools in
functional genomics that provide unique insight into healthy,
diseased or drug-treated cells. The company's expertise in advanced
molecular biology techniques and computational analysis has
resulted in the recent launch of tangerine® gene expression
profiling, a proprietary solution that reveals a whole genome
expression profile in a single experiment.
High coverage and sensitivity ensure complete profiles of expressed
genes, giving researchers the ability to study gene regulation
in any disease or eukaryotic model, since there is no prerequisite
for sequence data. The tangerine technology is based on lectrophoresis,
proprietary databases and algorithms that generate gene expression
profiles. Incorporating such comprehensive gene expression profiling
at key stages in drug discovery significantly improves selection
of targets and lead compounds, leading to well-validated drug
candidates and expediting development of a strong pharmaceuticals
portfolio.
Questions regarding this press release
or other issues should
be directed to:
Dr. Linnarsson, Chief Technology Officer, +46 8 50 88
47 18
or
Ms. Erika Johnson, Chief Financial Officer, +46 8 50
88 47 03
or
Mr. Martin Vidaeus, Manager Market Development, +46 8
50 88 47 29.
Disclaimer
Statements in this press release that
are not strictly historical may be forward-looking and include
risks and uncertainties. Although based on the company’s current
expectations, it should be duly noted that a variety of factors
could cause actual results and experiences to differ materially
from those expressed herein. Risks and uncertainties include,
but are not limited to, risks associated with the management
of growth and international operations (including effects of
currency fluctuations), variability of operating results, unforeseen
changes in the pharmaceutical markets, market competition, rapid
or unexpected changes in technologies, fluctuations in product
demand, difficulties to successfully develop, adapt, produce
or commercialize products, the ability to identify and develop
new products and to differentiate products from those of competitors,
as well as various legal hazards.
The Global Genomics (SM) logo and tangerine (R) are service
and registered trademarks, respectively, of Global Genomics
AB.
|
|
